JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GERBER, N.
Right arrow Articles by ARNOLD, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GERBER, N.
Right arrow Articles by ARNOLD, K.
Journal of Pharmacology And Experimental Therapeutics, Vol. 167, Issue 1, 77-90, 1969
Copyright © 1969 by American Society for Pharmacology and Experimental Therapeutics


STUDIES ON THE METABOLISM OF DIPHENYLHYDANTOIN IN MICE

NICHOLAS GERBER 1 and KEITH ARNOLD 1

1 Department of Medicine (Division of Clinical Pharmacology), The Johns Hopkins University School of Medicine, Baltimore, Maryland

The rate of disappearance of diphenylhydantoin (DPH) has been measured in mice given different doses ranging from 125 g to 1250 g. The biologic half-life (Tfrac12) of DPH in mice increases as the dose increases and ranges from 5 hr in mice given 125 g each to 16 hr in mice given 1 mg each. The rate of disappearance of DPH does not follow first-order kinetics in five of the six doses studied. An increase in the rate of disappearance of DPH in mice given 1 mg occurs after 16 hr. The increase in rate is associated with a stimulation of the drug-metabolizing liver microsomal enzymes. Treatment of mice with a single dose of 1 mg of DPH results in a significant increase in liver microsomal protein, zoxazolamine hydroxylase activity and cytochrome P450 content. Treatment of mice with 1 mg of DPH daily for 4 days also increases liver weight and liver protein and causes a proliferation of the smooth endoplasmic reticulum. A subsequent dose of 1 mg of DPH is metabolized more rapidly in these mice (Tfrac12 = 7.5 hr) compared with controls ( Tfrac12 = 16 hr), and the disappearance more closely follows first-order kinetics. Four days of treatment of each mouse with 1 mg daily of DPH results in a reduction in hexobarbital sleeping time and zoxazolamine paralysis time 40 hr after the last injection of DPH. There is also increased hexobarbital oxidase activity and zoxazolamine hydroxylase activity in liver microsomes of these mice. SKF 525-A (beta-diethylaminoethyl diphenylpropyl acetate) (50 mg/kg) and cycloheximide (100 mg/kg) pretreatment decreases the rate of disappearance of DPH.

Submitted on September 16, 1968
Accepted on January 10, 1969







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics.